Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 24 Sep 2025
In a recent cross-sectional study, researchers from Pennington Biomedical Research Center found that severe obesity is associated with a lower rate of cancer screenings. In their paper published in JAMA Network Open, "Obesity ...
Read Full NewsThe World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning that the highly addictive products were being...
Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.
The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.
1.
Young adults who are obese are at risk for 17 different types of cancer in the future.
2.
Researchers find distinct cell receptors with the potential for new treatments.
3.
Early palliative care billing up from 2010 to 2019 for advanced cancer
4.
Lymph node transfer reduces arm swelling after breast cancer surgery, study shows
5.
Taking vitamin D daily decreased cancer mortality, according to a study.
1.
Reshaping the Battlefield Through Tumor Microenvironment Modulation for Cancer Therapy
2.
What are Acanthocytes? Understanding the Role of Spiky Red Blood Cells
3.
Exploring the Unknown: Unveiling the Mysteries of GIST Tumors
4.
Uncovering the Mystery of the Sessile Serrated Adenoma
5.
Demystifying Hematoma Rectus Sheath: Knowing the Symptoms and Causes
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part IV
2.
Targeting Oncologic Drivers with Dacomitinib: A New Approach to Lung Cancer Treatment
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
4.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
5.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge